Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Galmed Pharmaceuticals Ltd. (GLMD : NSDQ)

• Company Description    Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $2.03 Daily Weekly Monthly 20 Day Moving Average: 389,444 shares Shares Outstanding: 1.65 (millions) Market Capitalization: $3.36 (millions) Beta: 0.60 52 Week High: $13.58 52 Week Low: $1.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 26.09% 21.36% 12 Week 47.10% 23.73% Year To Date -36.36% -40.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 16 ABBA HILLEL ROAD - RAMAT GAN,L3 5250608 ISR ph: 972-3693-8448 fax: 972-3693-8447 investor.relations@galmedpharma.com http://www.galmedpharma.com

• General Corporate Information    Officers Allen Baharaff - Chief Executive Officer and President Amir Poshinski - Chairman Guy Nehemya - Chief Operating Officer Doron Cohen - Chief Financial Officer Yohai Stenzler - Chief Accounting Officer Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: M47238148 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/27/25 Share - Related Items Shares Outstanding: 1.65 Most Recent Split Date: 8.00 (0.08:1) Beta: 0.60 Market Capitalization: $3.36 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/27/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.20 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 77.55% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -32.21 12/31/24 - -35.60 ROA 06/30/25 - - 03/31/25 - -28.59 12/31/24 - -31.37 Current Ratio 06/30/25 - - 03/31/25 - 9.02 12/31/24 - 7.42 Quick Ratio 06/30/25 - - 03/31/25 - 9.02 12/31/24 - 7.42 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 10.20 12/31/24 - 9.87 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©